 Shares of Enzo Biochem Inc. rallied 7.7 in premarket trading on Monday after the company said it received an emergency use authorization from the Food and Drug Administration for its COVID-19 diagnostic test. The regulator issued the EUA on July 7. It has granted emergency authorization to at least 137 diagnostic tests during the COVID-19 pandemic. Enzos stock is up 8.7 year-to-date. The SP; 500 has declined 1.4 since the start of the year. 